Pipeline

Our novel gene-based medicines and other collaborative development products have the potential to transform treatment prospects, thus improving the quality and duration of life for patients with debilitating and life threatening diseases.

A review of the in-house proprietary pipeline is currently ongoing with the review expected to be finalised in the fourth quarter of 2021.  The lead programme is OXB-302 which targets 5T4, this is currently being investigated in Acute Myeloid Leukaemia.

Loading...
Loading...
Loading...
Loading...